TRxADE HEALTH Dirección

Dirección controles de criterios 3/4

El CEO de TRxADE HEALTH's es Suren Ajjarapu , nombrado en Jan 2014, tiene una permanencia de 9.67 años. compensación anual total es $414.23K, compuesta por 85.5% salario y 14.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 12.16% de las acciones de la empresa, por valor de €1.06M. La antigüedad media del equipo directivo y de la junta directiva es de 9.3 años y 8.2 años, respectivamente.

Información clave

Suren Ajjarapu

Chief Executive Officer (CEO)

US$414.2k

Compensación total

Porcentaje del salario del CEO	85.5%
Permanencia del CEO	9.7yrs
Participación del CEO	12.2%
Permanencia media de la dirección	9.3yrs
Promedio de permanencia en la Junta Directiva	8.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Suren Ajjarapu en comparación con los beneficios de TRxADE HEALTH?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-US$4m
Mar 31 2023	n/a	n/a	-US$3m
Dec 31 2022	US$414k	US$354k	-US$3m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$388k	US$372k	-US$5m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$667k	US$286k	-US$3m
Sep 30 2020	n/a	n/a	-US$719k
Jun 30 2020	n/a	n/a	-US$830k
Mar 31 2020	n/a	n/a	-US$229k
Dec 31 2019	US$750k	US$250k	-US$284k
Sep 30 2019	n/a	n/a	US$23k
Jun 30 2019	n/a	n/a	US$89k
Mar 31 2019	n/a	n/a	US$52k
Dec 31 2018	US$200k	US$200k	US$9k
Sep 30 2018	n/a	n/a	US$337k
Jun 30 2018	n/a	n/a	US$319k
Mar 31 2018	n/a	n/a	US$292k
Dec 31 2017	US$149k	US$149k	US$289k
Sep 30 2017	n/a	n/a	US$88k
Jun 30 2017	n/a	n/a	-US$284k
Mar 31 2017	n/a	n/a	-US$922k
Dec 31 2016	US$199k	US$149k	-US$1m

Compensación vs. Mercado: La compensación total ($USD414.23K) de Suren está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Suren ha aumentado mientras la empresa no es rentable.

CEO

Suren Ajjarapu (52 yo)

9.7yrs

Permanencia

US$414,231

Compensación

Mr. Surendra K. Ajjarapu, also known as Suren, serves as Chairman of the Board, Chief Executive Officer of PowerUp Acquisition Corp. since August 18, 2023. He serves as Chief Executive Officer and Chairman...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Surendra Ajjarapu	Founder	9.7yrs	US$414.23k	12.16% $ 1.1m
Prashant Patel	Founder	9.7yrs	US$157.04k	11.11% $ 970.2k
Ramesh Kenchappa	Chief Scientific Officer	9yrs	sin datos	sin datos
David Saslow	Inhouse Counsel	no data	sin datos	sin datos
Jariel Morales	Executive Vice President	6.4yrs	sin datos	sin datos

9.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 4E40 es experimentado (9.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Surendra Ajjarapu	Founder	9.7yrs	US$414.23k	12.16% $ 1.1m
Prashant Patel	Founder	9.7yrs	US$157.04k	11.11% $ 970.2k
Michael Peterson	Independent Director	less than a year	US$96.25k	0% $ 0
Candice Beaumont	Director	less than a year	sin datos	sin datos
A. Newell	Independent Director	less than a year	US$59.35k	0% $ 0
Donald Anderson	Member of Advisory Board	8.2yrs	sin datos	sin datos
Donald Fell	Independent Director	9.7yrs	US$129.25k	0.39% $ 34.4k

8.2yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 4E40 se considera experimentada (8.2 años de antigüedad promedio).

TRxADE HEALTH Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH, INC Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

Recent updates

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad